Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 15,134 shares at $327.43 ($4.9M) on 2023-04-12, disclosed to the SEC on 2023-04-14.
Scheduled sale ($4.9M) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $325.70 | 874 | $285K | 5.8% |
| 2 | $325.70 | 874 | $285K | 5.8% |
| 3 | $326.45 | 4,068 | $1.3M | 26.9% |
| 4 | $326.45 | 4,068 | $1.3M | 26.9% |
| 5 | $327.43 | 2,625 | $860K | 17.4% |
| 6 | $327.43 | 2,625 |
| $860K |
| 17.4% |
| Total | $326.70 avg | 15,134 | $4.9M | 100% |
| Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |
| VRTX | SELL | 2023-02-16 | $1.3M | — | Filing → |